FDA approves pembrolizumab with chemotherapy for platinum-resistant ovarian cancer, showing significant survival benefits in ...

Armed with what CEO Robert Davis called the “broadest and widest pipeline we’ve had in years,” Merck is preparing for its ...

Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals ...

Investing.com -- The U.S. Food and Drug Administration (FDA) has approved Merck ’s pembrolizumab (Keytruda) and pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for treating certain ...

Merck’s fourth quarter was marked by continued demand for its oncology and cardiometabolic franchises, as well as the impact ...

Merck & Co., Inc. is rated a Buy due to robust asset portfolio, strong shareholder return, and buybacks. Learn more about MRK ...

Merck & Co. is no longer a deep-value patent cliff trade but a fairly valued defensive compounder. Read why I have downgraded ...

Merck posted a modest Q4 earnings beat with adjusted EPS of $2.04 on $16.4 billion in revenue. ・The company is planning ...

Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...

Gilead Sciences reported positive Phase 3 results for Trodelvy combined with Keytruda in first-line PD-L1+ metastatic ...

Moderna (NASDAQ: MRNA) has been on fire this year, with the biotech's shares up by 39% through Feb. 6. This isn't due to the ...

After a surprise failure in advanced liver cancer, Merck & Co. and Eisai are hoping new data can make their Keytruda-Lenvima combination a standard of care in intermediate-stage disease. The positive ...